TESTING AND CERTIFICATE OF ANALYSIS Sample Clauses

TESTING AND CERTIFICATE OF ANALYSIS. Prior to the use of any article(s), chemical or other component(s) or composition(s) in the MANUFACTURING of the GOODS, SELLER shall, at SELLER’s expense, test, or otherwise determine, that such article(s), chemical or other component(s) or composition(s) are in compliance with the SPECIFICATIONS and the QUALITY AGREEMENT (“GMP”). In no case shall SELLER use any article(s), chemical or other component(s) or composition(s) not in compliance with the SPECIFICATIONS and GMP in the MANUFACTURING of the GOODS. SELLER’s quality assurance department shall provide certificates of analysis to BUYER relating to each shipment of GOODS concurrently with the DELIVERY of such GOODS.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
TESTING AND CERTIFICATE OF ANALYSIS. Before releasing any batch of the Materials, OSGP shall test for the compliance of such batch with all Registered tests for their site and cGMP’s. OSGP’s Quality Assurance department at the Norwich Plant shall oversee and assure the testing is completed by the OSGP Quality Control laboratory at the Norwich Plant. Copies of raw material, manufacturing, and inspection records will be made available for review by P&G representatives. Copies of manufacturing records and Calcium Contract for Europe PFI 11-9-0512 Rev. 1/24/06 certificates of analysis incorporating such certification, in the form attached hereto as Schedule E, shall be provided to P&G with each shipment of Product(s) for each batch and/or partial batch contained in the shipment. All such copies shall be sent to the addressees specified by P&G.
Sample 1
TESTING AND CERTIFICATE OF ANALYSIS. Before releasing any Batch of Product hereunder, NOVEN shall test Product and check the compliance of such Batch with the Specifications. Such compliance check shall be performed by NOVEN’s Quality Assurance Control department and shall be certified by the head of such department (or his/her designee). Copies of the certificate of analysis and cGMP conformity certification, along with any other pertinent manufacturing or testing documentation, shall be sent to P&GP in accordance with the terms and conditions of the Quality Assurance Agreement.
Sample 1
TESTING AND CERTIFICATE OF ANALYSIS. NPI shall provide a certificate of analysis ("Certificate of Analysis") to Celgene or its designated agent with each shipment of supplied Product made hereunder. Such Certificate of Analysis shall certify with respect to each shipment and lot (identified by batch/lot or control number): (i) the quantity of the shipment and (ii) that the Product delivered was manufactured in accordance with the Specifications and the Master Batch Records and documented according to requirements of Laws, Rules and Regulations and applicable production standard operating procedures.
Sample 1
TESTING AND CERTIFICATE OF ANALYSIS. Naturo shall provide a Certificate of Analysis in compliance with applicable Laws, Rules and Regulations (“Certificate of Analysis”) to BevCanna, with each batch of Finished Product made available hereunder. Such Certificate of Analysis shall certify with respect to each shipment and lot (identified by batch/lot or control number): (a) the quantity of the shipment; (b) the analytical test results for a specified lot of Finished Products provided to BevCanna hereunder; and (c) that the Finished Product made available to BevCanna was Manufactured in accordance with the Specifications and the master batch records and documented according to requirements of Laws, Rules and Regulations and production standard operating procedures.
Sample 1
TESTING AND CERTIFICATE OF ANALYSIS. Before releasing any lot of ----------------------------------- the Compound, Supplier and its Affiliates shall confirm the compliance of such lot with the Specifications. Such compliance check shall be performed by Supplier's Quality Assurance/Quality Control department and shall be certified by the head of such department (or his/her designee). Copies of the certificate of analysis incorporating such certification and manufacturing and analytical/microbiological records, shall be sent to Interneuron: (i) with each shipment of the Compound containing material from such lot, and (ii) within ten (10) business days of the first shipment of the Compound containing material from such lot. All such copies shall be sent to the addressees specified by Interneuron or, if no addressee is specified, to the place of delivery of the Compound.
Sample 1
TESTING AND CERTIFICATE OF ANALYSIS. DURA shall provide to FHP or its designated agent the certificate of analysis provided to DURA by P&G ("Certificate of Analysis"), with each shipment of Supplied Product made hereunder. Such Certificate of Analysis shall certify with respect to each shipment and lot (identified by batch or lot number) (i) the quantity of the shipment, (ii) the Supplied Product flavor, and (iii) that the Supplied Product delivered was manufactured in accordance with the Specifications and the Master Batch Records and documented according to requirements of CGMP and Production SOPs. FHP shall be under no obligation to accept any shipment of Supplied Product without an accompanying Certificate of Analysis.
Sample 1
AutoNDA by SimpleDocs
TESTING AND CERTIFICATE OF ANALYSIS. Before releasing any batch of the Materials, AHS shall test for the compliance of such batch with all applicable tests for their site, cGMPs and Release Specifications. AHS’ quality assurance department at the Orlando Lab shall oversee and assure the testing is completed by the AHS quality control laboratory at the Orlando Lab. Copies of raw material, manufacturing, and inspection records will be made available for review by Hemostemix representatives. The costs of testing requested by Hemostemix that is not part of the manufacturing process as defined in the Protocol will be charged at AHS cost to Hemostemix. In the event of any failed test, or allegedly failed test, Section 4.3 (Quality Disputes) will apply.
Sample 1

Related to TESTING AND CERTIFICATE OF ANALYSIS

  • Certificate of Analysis Seller shall provide a certificate of analysis and other documents as defined in the Quality Agreement for any Product to be released hereunder, in a form in accordance with the cGMPs and all other applicable Regulatory Requirements and Product Specifications and as shall be agreed upon by the parties. For any batch that initially failed to meet any Product Specification, the certificate of analysis shall document the exception. Products that do not meet dissolution specifications at USP Stage I and II testing shall not be accepted by Buyer (and such requirement shall be included in the Product Specifications/Quality Manual).

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Escrow Format Specification Deposit’s Format. Registry objects, such as domains, contacts, name servers, registrars, etc. will be compiled into a file constructed as described in draft-xxxxx-xxxxxxx-registry-data-escrow, see Part A, Section 9, reference 1 of this Specification and draft-xxxxx-xxxxxxx-dnrd-objects-mapping, see Part A, Section 9, reference 2 of this Specification (collectively, the “DNDE Specification”). The DNDE Specification describes some elements as optional; Registry Operator will include those elements in the Deposits if they are available. If not already an RFC, Registry Operator will use the most recent draft version of the DNDE Specification available at the Effective Date. Registry Operator may at its election use newer versions of the DNDE Specification after the Effective Date. Once the DNDE Specification is published as an RFC, Registry Operator will implement that version of the DNDE Specification, no later than one hundred eighty (180) calendar days after. UTF-8 character encoding will be used.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Escrow Analysis If applicable, with respect to each Mortgage Loan, the Seller has within the last twelve months (unless such Mortgage was originated within such twelve month period) analyzed the required Escrow Payments for each Mortgage and adjusted the amount of such payments so that, assuming all required payments are timely made, any deficiency will be eliminated on or before the first anniversary of such analysis, or any overage will be refunded to the Mortgagor, in accordance with RESPA and any other applicable law;

  • Drug-Free Workplace Certification As required by Executive Order No. 90-5 dated April 12, 1990, issued by the Governor of Indiana, the Company hereby covenants and agrees to make a good faith effort to provide and maintain a drug-free workplace at the Project Location. The Company will give written notice to the IEDC within ten (10) days after receiving actual notice that the Company, or an employee of the Company in the State of Indiana, has been convicted of a criminal drug violation occurring in the workplace. False certification or violation of this certification may result in sanctions including, but not limited to, suspension of payments under the Agreement, termination of the Agreement and/or debarment of contracting opportunities with the State for up to three (3) years. In addition to the provisions of the above paragraph, if the total amount set forth in the Agreement is in excess of $25,000.00, the Company agrees that it will provide a drug-free workplace by: A. Publishing and providing to all of its employees a statement notifying them that the unlawful manufacture, distribution, dispensing, possession or use of a controlled substance is prohibited in the Company’s workplace, and specifying the actions that will be taken against employees for violations of such prohibition;

  • ODUF Packing Specifications 6.3.1 A pack will contain a minimum of one message record or a maximum of 99,999 message records plus a pack header record and a pack trailer record. One transmission can contain a maximum of 99 packs and a minimum of one pack.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • SAMPLE (If applicable and the project has specifications, insert the specifications into this section.)

  • Evaluation, Testing, and Monitoring 1. The System Agency may review, test, evaluate and monitor Grantee’s Products and services, as well as associated documentation and technical support for compliance with the Accessibility Standards. Review, testing, evaluation and monitoring may be conducted before and after the award of a contract. Testing and monitoring may include user acceptance testing. Neither the review, testing (including acceptance testing), evaluation or monitoring of any Product or service, nor the absence of review, testing, evaluation or monitoring, will result in a waiver of the State’s right to contest the Grantee’s assertion of compliance with the Accessibility Standards. 2. Grantee agrees to cooperate fully and provide the System Agency and its representatives timely access to Products, records, and other items and information needed to conduct such review, evaluation, testing, and monitoring.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!